Loading stock data…
$3.72-0.07 (-1.85%)
Q/C Technologies, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing therapeutic platforms based on various therapeutic targets.
Q/C Technologies, Inc. in the Technology sector is trading at $3.72. The stock is currently near its 52-week low of $2.50, remaining 9.9% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 30/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$1.86M↑ | -$3.71M↓ | -$1.52M↑ | -$1.87M↑ | -$2.47M |
| Net Income | -$1.24M↑ | -$5.89M↓ | -$2.81M↓ | -$1.80M↓ | -$1.12M |
Q/C Technologies, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing therapeutic platforms based on various therapeutic targets. The company develops Isomyosamine, a clinical stage small molecule that regulates t...